The successful launch of the AI tool, developed in collaboration with a major software provider, signifies a significant step towards achieving OTC status for STENDRA. This development is likely to be viewed positively by investors as it demonstrates progress in the company's drug development programs and its ability to meet regulatory requirements. The focus on optimizing the safe administration of STENDRA through AI and the ongoing Human Factors study to assess the effectiveness of the web app for patient self-screening are critical components that could enhance the drug's market potential and regulatory approval prospects.